Whalesbook
Profit Plummets Amid Revenue Drop
Cohance Lifesciences Ltd. has revealed a severe downturn in its fourth-quarter financial results, marked by a dramatic plunge in net profit and a significant drop in revenue. This performance marks a stark contrast to the prior year's figures and signals considerable challenges for the company.
Margins and EBITDA Fall Sharply
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a substantial 60% year-on-year decline, falling to ₹98.7 crore from ₹229.2 crore. This led to a sharp compression in the EBITDA margin, which shrank to 15.9% from 27.3%. While gross margins improved to 65.4% and adjusted EBITDA stood at ₹130 crore for the quarter, these figures relate to specific adjustments and individual segment performance. The consolidated results faced the full impact of operational challenges.
Outlook: Recovery Expected in FY27
Looking ahead, management forecasts growth to resume in the second half of fiscal year 2027. The first quarter of FY27 is anticipated to mark the lowest financial performance for both revenue and EBITDA. The company expects this recovery to be fueled by the execution of current programs, successful customer wins, and improved utilization of its manufacturing platforms.
Pipeline Shows Resilience
Despite the near-term financial pressures, Cohance Lifesciences highlighted a robust pipeline. The company reported consistent inflows for proposals covering small molecules, Antibody-Drug Conjugates (ADCs), and complex chemistries. Management is currently focused on enhancing win rates for critical later-stage pipeline projects, aiming to secure future growth.